Navigation Links
Alfacell Receives NASDAQ Delisting Letter
Date:8/1/2008

believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, the company's ability to successfully appeal the NASDAQ's delisting determination and to regain its compliance with NASDAQ continued listing standards and maintain such compliance, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact:

David Schull or Wendy Lau

Russo Partners

212-845-4271

David.Schull@russopartnersllc.com

Wendy.Lau@russopartnersllc.com

Investor Contact:

Andreas Marathovouniotis

Russo Partners

212-845-4235

Andreas.Marathis@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacell Receives NASDAQ Non-Compliance Notification
2. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
3. Alfacell Announces Retirement of Chief Executive Officer
4. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
5. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
6. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
7. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Alfacell to Present at BIO InvestorForum 2007
10. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
11. Workforce Alliance Receives U.S. Labor Departments Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Drought-Tolerance Technology Crosses Another Key Regulatory MilestoneLONDON, March 10 ... development in breeding and biotechnology has contributed to a ... Seeds and Genomics segment since 2001. This is ... President of International Commercial, will tell investors today as ...
... Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a ... announce its fourth quarter and year ended December 31, ... the markets close. The announcement will be followed by ... Pacific time. Orexigen management will host the call and ...
... Engineering Know-how, and Smart Plastics Expertise Combine ... Life SciencesN. BILLERICA, Mass., March 9 Seahorse ... cell based metabolic assays today announced the acquisition ... biologic drug manufacturing. The two companies will ...
Cached Biology Technology:Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 3Seahorse Bioscience, Inc. Acquires BioProcessors Corp. 2
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... era of increasing concern about the prevalence of ... a promising new pathway to disabling disease: blocking ... The scientists showed how bacterial siderophore, a small ... to fan bacterial growth as well as ... this infection process. Their findings appear in a ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... Park, Pa. -- A little known fungus tucked away ... insect munch through the hardest of woods according to ... discovery could lead to innovative methods of controlling the ... breaking down plant biomass for generating biofuels. Microbes ...
... struggled to understand the decline and slow recovery of ... and food fish native to New England rivers. Biologists ... the U.S. and Canada, but specific causes are difficult ... associated technology may provide some answers. Thirty ...
... DCChildren,s National Medical Center immunologist and blood and marrow ... serve as the study co-chair for a new national ... blood transplants for severe sickle cell disease ... medical institutions in the first-ever Phase II clinical trial ...
Cached Biology News:Novel fungus helps beetles to digest hard wood 2Novel fungus helps beetles to digest hard wood 3Signals from the Atlantic salmon highway 2Signals from the Atlantic salmon highway 3Signals from the Atlantic salmon highway 4Children's national co-leads nationwide study of landmark sickle cell treatment 2
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: